Kornimate/medical-research-clean huggingface dataset:
alport syndrome treatments and outcomes registry

Conditions: Alport Syndrome

Summary: astor's primary purpose is to enroll families and patients with a history of alport syndrome in a central registry. the information we gather will be used as a basis for studies designed to test potential treatments for alport syndrome. astor also aims to provide patients, families and physicians with the most up-to-date information about alport syndrome.

the university of minnesota's department of pediatrics has created the alport syndrome treatments and outcomes registry (astor). astor's primary purpose is to enroll families and patients with a history of alport syndrome in a central registry. the information we gather will be used as a basis for studies designed to test potential treatments for alport syndrome. astor also aims to provide patients, families and physicians with the most up-to-date information about alport syndrome. you can help doctors learn more about alport syndrome and test possible treatments for the disease by enrolling in astor. since alport syndrome is a rare disease it is essential for astor to enroll as many patients as possible. together, you and others facing the challenges of alport syndrome can provide valuable information that will help doctors better understand the disease and in turn, help patients with alport syndrome now and in the future.

Eligibility criteria:
inclusion criteria: history of a diagnosis of alport syndrome, family or individuals need to be able to comprehend the consent and hipaa forms written in the english language. exclusion criteria: uncertain diagnosis of alport syndrome.

Keywords: alport syndrome x linked autosomal dominant alport syndrome glomerular basement membrane hereditary nephritis familial benign haematuria type iv collagen hereditary nephritis with neurosensory deafness vison loss
effects of combination therapy of statin and ascorbic acid for prevention of contrast-induced nephropathy

Conditions: Contrast-induced Nephropathy; Statin; Ascorbic Acid; AKI

Summary: to evaluate the benefit for statin use in prevention of of ci-aki after computed tomography urogram (ctu).


Eligibility criteria:
inclusion criteria: * planned computed tomography urogram (ctu) * statin naive, or not on statin treatment for at least 14 day exclusion criteria: * history of liver disease or elevated serum transaminases * history of rhabdomyolysis or elevated creatinine kinase * history of iodinated cm use within 14 days before randomization * history of n-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure. * history of hypersensitivity reaction to contrast media * pregnancy or lactation * acute renal failure * end-stage renal disease requiring dialysis * cardiogenic shock or pulmonary edema * multiple myeloma
erciyes university faculty of health sciences

Conditions: Hemodialysis

Summary: sleep disorders are important to place among the symptoms frequently seen in hemodialysis patients. among sleep disorders, restless legs syndrome is the most common. restless legs syndrome, seen in patients receiving hemodialysis treatment, causes excessive daytime sleepiness and negatively affects the sleep quality of individuals.


Eligibility criteria:
inclusion criteria: * those who are 18 years or older, * not pregnant and not planning a pregnancy, * having been diagnosed with restless leg syndrome according to the restless leg syndrome diagnostic scale and by a physician, * having at least mild restless leg syndrome according to the restless leg syndrome severity rating scale, * scoring 11 or above on the epworth sleepiness scale, * psqi score an average of 5 and above, * receiving hemodialysis treatment in hemodialysis units for at least 3 months and 3 sessions per week, * continuing dialysis treatment in the same institution, * able to walk independently, * no changes in the treatment program before the massage and throughout the research process, * not having any allergies to the oils to be used, * individuals who can understand and communicate with turkish will be included in the research exclusion criteria: * those who are sensitive and/or have any allergies to the lavender oil to be used, * those who have lower leg problems that would prevent them from applying massage to the lower leg area, * have a history of mental or physical disability, including peripheral neuropathy, vascular problems in the legs, * epilepsy, alzheimer's, parkinson's, multiple sclerosis, etc. those with a diagnosed neurological disease such as * pre-implemented, * those with respiratory system disorders, * patients who used other complementary and integrative therapies methods during the study period will be excluded from the study

Keywords: hemodialysis restless leg syndrome aromatherapy massage sleep quality lavender oil
ranibizumab (lucentis) for polypoidal choroidal vasculopathy

Conditions: Polypoidal Choroidal Vasculopathy

Summary: this phase i/ii safety study is designed to investigate the safety and efficacy of ranibizumab (lucentis) in the treatment of polypoidal choroidal vasculopathy (pcv), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. these abnormal blood vessels can bleed or leak fluid, causing disruption of normal retinal function and vision loss. ranibizumab is a drug that is fda-approved for the treatment of wet age-related macular degeneration (amd) and is injected directly into the eye. given the efficacy of ranibizumab in the treatment of wet amd, and the postulated similarity between the disease mechanisms involved in both wet amd and pcv, we believe ranibizumab will have a beneficial effect on visual function in patients with pcv.

please see above description. phase i/ii safety study; prospective, open-label, single-center, non-randomized, uncontrolled, consecutive interventional case series. enrolled patients are \>35 years old and display exudative, active polypoidal choroidal vasculopathy (pcv) in 1 eye. pcv is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography. eyes receive 3 consecutive, monthly intravitreal ranibizumab injections (0.5 mg or 0.3 mg/0.05 cc) followed by monthly evaluations with the option of additional intravitreal ranibizumab or alternative treatments at the discretion of the investigator. baseline and follow-up evaluations include medical history, blood pressure, physical examination, early treatment diabetic rentinopathy study (etdrs) best-corrected visual acuity (bcva), intraocular pressure measurement, complete ophthalmologic examination, fundus photography, fluorescein/ indocyanine green (icg) angiography, and optical coherence tomography (oct).

Eligibility criteria:
inclusion criteria: * age \>35 years * exudative, active pcv in 1 eye. * pcv is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography. exclusion criteria: * age \<35 years * prior treatment with non-ranibizumab therapies (e.g., laser, surgery, or bevacizumab)

Keywords: polypoidal choroidal vasculopathy choroidal neovascularization ranibizumab lucentis
preperitoneal versus pre-trasversalis hernia repair

Conditions: Direct Inguinal Hernia; Indirect Inguinal Hernia

Summary: chronic pain rate is from 0 to 50% after prosthetic groin hernia repair. we compared two anterior technique positioning the mesh in the pre-trasversalis space vs preperitoneal space to assess any differences in term of chronic pain and early and late complications

chronic pain is evaluated in all presenting types (achy, dull, etc.) moreover foreing body sensation, wall stiffness, paresthesia and numbness are controlled in each patients. limiting of daily, working, sport and sexual activities (disejaculation) are reported as well.

Eligibility criteria:
inclusion criteria: * 18 years older exclusion criteria: * recurrent inguinal hernia * previous low abdominal operation

Keywords: inguinal hernia groin hernia chronic pain mesh repair
treatment with iv iron in hospitalized patients with severe heart failure but without iron deficiency

Conditions: Heart Failure

Summary: patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. the study group will receive 2 doses of iv iron (iron carboxymaltose). the control group will receive standard of care alone. the study will test for the effects of the additional iv iron on the symptoms, clinical picture and quality of life of the treated patients.

patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. the study group will receive 2 doses of iv iron (iron carboxymaltose). the control group will receive standard of care alone. the study will test for the effects of the additional iv iron on the symptoms, clinical picture and quality of life of the treated patients. the parameters that will be measured will include clinical, lab, echo, and quality of life questionnaires.

Eligibility criteria:
inclusion criteria: * heart failure grade 3-4 * heart echo ef\< 40% (ejection fraction) * hb \> 10 mg/dl * iron\> 50 mic/dl * iron/ transferrin rate \> 20% exclusion criteria: * infection * acute ischemia * patients that didn't receive the standard of care during 3 days before investigational product administration * hemochromatosis * known allergy to one of the products of the investigational product. * macrocytic anemia * iron excess * pregnant women * mentally disabled patients which can't give their concent properly.
study on ai recognition system of heart sound in congenital heart disease screening

Conditions: Congenital Heart Disease in Children

Summary: the objective of this study is to establish ai algorithm based on the deep learning to strengthen the ability to classify the heart murmurs of healthy people and different major or other subdivided congenital heart diseases(chds) and to evaluate the effectiveness of artificial intelligence technology-assisted heart sound recognition system (referred to as: heart sound ai recognition system) for multi-center chd screening.

this is a multi-center cluster cross-sectional study in china. heart sounds will be collected by auscultation using an electronic stethoscope in children (0 \~ 18 years old) confirmed with or without chds by echocardiography during outpatient or hospitalization in 10 pediatric medical centers. heart sounds will be visualized as phonocardiogram, and feature extraction will be done after classification of normal and abnormal heart sounds and labeling the characteristics of heart murmurs by pediatric cardiovascular specialists. artificial intelligence algorithm (machine learning, deep learning, etc.) will be trained to build a heart sounds recognition system with the data mentioned above.we will use the receiver operating characteristic (roc) curve to compare the ability of recognition and classification of abnormal heart sounds between different artificial intelligence algorithm. taken the results of echocardiography as the gold standard, we will use the evaluation indexes,such as sensitivity, specificity, accuracy, positive predictive value, negative predictive value, etc, to compare the diagnostic capacity of chd screening between the ai recognition system and human cardiovascular pediatricians. our target is to use artificial intelligence technology to assist heart auscultation for chd screening.

Eligibility criteria:
inclusion criteria: 1. 0 \~ 18 years of age, regardless of gender ； 2. children with or without congenital heart disease confirmed by echocardiography； 3. on the basis of informed consent，willing to cooperate with our group. exclusion criteria: 1. ≥ 18 years of age; 2. children who can not undergo echocardiography or other related tests; 3. subjects who refuse to join in, or who are unwilling to cooperate with the provision of diagnostic and therapeutic data for further analysis and research.

Keywords: congenital heart disease artificial intelligence heart sound
cognitive decline and underlying mechanisms in asymptomatic intracranial artery stenosis patients

Conditions: Asymptomatic Intracranial Stenosis; Cognitive Impairment; Cerebrovascular Event

Summary: the purpose of this study is to explore the mechanism of cognitive impairment in patients with asymptomatic intracranial atherosclerotic stenosis(icas),and to examine the natural history and the pathogenesis of asymptomatic icas.

all participants underwent a medical evaluation that included routine laboratory studies before and after 1- and 2-years follow-up. upon meeting the inclusion criteria and providing informed consent, each participant will complete a battery measure of neuropsychological tests, blood sample collection, and magnetic resonance imaging scan after enrollment and after 1- and 2-years follow-up. about 100 participants were included in this study. a series of neuropsychological tests were obtained by a trained investigator to assess. the tests include the evaluation of global cognitive function and multiple individual cognitive domains. the various tasks and questionnaires to measure cognition function including montreal cognitive assessment(moca), mini mental state examination(mmse), chinese auditory verbal learning test(cavlt), digital span test(dst), symbol digital modalities test(sdmt), stroop color test(stroop test), color trail test(ctt), rey-osterrieth complex figure(rocf), judgment of line orientation (jolo), verbal fluency test(vft), boston naming test (bnt) , lateralized attention network test(lant) etc, at the same time, the investigators also pay attention to the evaluation of participants' emotions by hamilton anxiety scale(hama),hamilton depression scale(hamd). furthermore, the memory as the primary outcome measure, this study focused on the immediate memory, delayed memory and recognition memory of patients with asymptomatic icas. blood sample will be collected for biological multiomics research. the patients will receive a magnetic resonance imaging scan in multi-modalities. after 1 and 2 years follow-up,the participants will be interviewed to obtain the same assessments, blood sample and magnetic resonance imaging scan in multi-modalities as before.

Eligibility criteria:
inclusion criteria: 1. patients with intracranial stenosis which was defined as stenosis of 50% or more in intracranial segment of internal carotid artery(c6-c7) and middle cerebral artery (m1). 2. the degree of stenosis was measured by transcranial doppler, computed magnetic resonance angiography (mra),tomography angiography (cta) and digital subtraction angiography (dsa). exclusion criteria: 1. history of stroke,transient ischemic attack,seizures or unexplained loss of consciousness. 2. organic brain defects on mri t1 or t2 images. 3. any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder). 4. implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator. history of substance abuse within the last 6 months.

Keywords: asymptomatic intracranial stenosis patients cognitive impairment cerebrovascular event
clinical effect evaluation of laparoscopic surgery for ovarian benign tumors by different approaches

Conditions: Laparoscope; Malignant Ovarian Tumor; Single-site Surgery

Summary: main purpose: to compare the intraoperative and postoperative recovery of laparoscopic surgery for ovarian benign tumors through different approaches; secondary objective: will vnotes increase the risk of cesarean section during pregnancy and affect the quality of sexual life after surgery.


Eligibility criteria:
inclusion criteria: preoperative consideration was for benign ovarian tumors requiring surgical treatment. exclusion criteria: * (1) ovarian malignant tumor or borderline tumor was considered before surgery or proved during surgery. (2) severe endometriosis, previous severe pelvic inflammation, peritonitis, and other serious pelvic adhesions are considered. (3) pregnancy status. (4) postoperative follow-up is not convenient and lost visitors.

Keywords: transumbilical laparoendoscopic single-site surgery,giant malignant ovarian tumor
study on the prognosis and effect of anti-diabetic drugs on type-2 diabetes mellitus with coronary artery disease

Conditions: Type 2 Diabetes; Coronary Artery Disease

Summary: the purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study the end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation


Eligibility criteria:
inclusion criteria: * coronary heart disease * type 2 diabetes exclusion criteria: * severe organ dysfunction, psychopathy, infection, neutropenia * congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy
treatment of relapsed t-cell acute lymphoblastic leukemia or t-lymphoblastic lymphoma with mabcampath

Conditions: Adult Acute Lymphocytic Leukemia T-cell; Lymphoma, Lymphoblastic

Summary: this study tests the effectivity and tolerability of treatment with alemtuzumab (mabcampath) in patients with relapsed or refractory t-cell acute lymphoblastic leukemia (t-all) or t-lymphoblastic lymphoma. in arm a, patients with refractory relapse receive a 2 week treatment with mabcampath followed by remission evaluation. in case of insufficient response, treatment with cladribine is added. in arm b, patients with molecular relapse (minimal residual disease) receive a 4 week treatment with mabcampath followed by remission evaluation. in both arms, treatment is continued in case of response for up to two months.


Eligibility criteria:
inclusion criteria: both arms: * t-all or t-lymphoblastic lymphoma * cd52-expression \> 20% * aged \>= 18 years * ecog/world health organization (who) performance status 0-2 * life expectancy of \> 2 months * contraception during, and for at least 6 months after, therapy * at least a 2 week interval to the last cycle of chemotherapy (decision in individual cases if rapid progression) * no persistent toxicity from earlier cycles * written informed consent arm 1: * evidence of mrd \> 10(-4) with confirmation beyond week 16 in the gmall-study 07/2003 arm 2: * relapse with failure to at least one salvage therapy or primary failure after induction therapy and at least one salvage therapy exclusion criteria: * substantial restrictions of heart, lung, liver, or kidney function * active infection, hiv seropositivity or cytomegalovirus (cmv) viraemia * pretreatment with mabcampath® * known anaphylaxis to humanised antibodies * permanent systemic therapy with corticosteroids * central nervous system (cns) involvement * extramedullary bulky disease * active secondary malignancies * pregnancy or nursing * mental disease or circumstances that prohibit compliance with the protocol procedures

Keywords: relapse t-all t-lbl mabcampath minimal residual disease lymphoma, lymphoblastic, t-cell
a long-term, follow-on safety study of four doses of opc-8212 (vesnarinone) in hiv-infected persons

Conditions: HIV Infections

Summary: to examine the continued safety and tolerability of four doses of vesnarinone in hiv-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.

patients who have completed a limited duration study (less than 12 months of continuous treatment) of vesnarinone on protocols fda 234a or fda 234b and who have no current signs or symptoms of aids-defining illnesses may roll over to this study and continue receiving their regimen of vesnarinone for 12 months beyond their original participation.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * chemoprophylaxis for pneumocystis carinii, candida, and mycobacteria. * acyclovir for acute treatment of herpes. exclusion criteria concurrent medication: excluded: * antiretroviral agents, including ddi, ddc, azt, and d4t. * immunosuppressive agents. * investigational hiv drugs/therapies including vaccines. * interferon or other immunomodulating agents. * corticosteroids (other than topical). * megestrol acetate. * agents known to cause neutropenia. * ganciclovir. * cytotoxic chemotherapy. concurrent treatment: excluded: * radiation therapy. patients with the following prior conditions are excluded: * poor compliance (less than 80 percent of drug taken) on the phase i protocol (fda 234a or fda 234b). * missed more than one clinic visit on the phase i protocol. prior medication: excluded: * acyclovir as prophylaxis for herpes within 48 hours prior to study entry. patients meet the following criteria: successful completion of short-term therapy with vesnarinone on fda 234a or fda 234b. active illicit drug abuse.

Keywords: acquired immunodeficiency syndrome antiviral agents vesnarinone